Literature DB >> 2645701

Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients.

M A Simpson1, P N Madras, A J Cornaby, T Etienne, R A Dempsey, G H Clowes, A P Monaco.   

Abstract

Urine cytology, plasma (P), and urinary (U) interleukin-2 (IL-2)* and IL-2 receptor (IL-2R) levels were evaluated as immunological monitoring techniques in 65 renal allograft recipients. Normal individuals showed normal urine cytology, IL-2(U) = 0, IL-2(P) = 0.4 +/- 0.1 ng/ml (mean +/- SEM) and IL-2R(P) = 318 +/- 26 U/ml. Stable transplants also showed normal urine cytology, no IL-2(U), IL-2(P) = 0.8 +/- 0.2 ng/ml, and IL-2R(P) = 326 +/- 29 U/ml. Rejection episodes (n = 21) were accompanied by cytologic changes, including lymphocyturia, exfoliation of immature tubular cells, platelet aggregates, and fibrin deposits. The corresponding lymphokine changes were IL-2(U) = 39.6 +/- 1.4 ng/ml, IL-2(P) = 79 +/- 21 ng/ml, and IL-2R = 1884 +/- 202 U/ml, all markedly increased. Successful treatment was associated with return of all parameters to normal; treatment failure was associated with continued abnormalities. Fourteen rejections unresponsive to Solumedrol (500 mg x 5 days) required OKT3 rescue (5 mg x 14 days). In the 11 that were reversed, onset of OKT3 therapy was characterized by markedly increased exfoliation of necrotic cellular debris, lymphocytes, and collecting duct cells. Interestingly, serum creatinine increases of 57.2 +/- 18.9% (range 25-90%) over pre-OKT3 levels were noted. Maximal changes occurred 48-72 hr after the first dose, followed by gradual return to normal. Rejections unresponsive to OKT3 (n = 3) showed no cytologic changes from the pretreatment mean creatinine increase of 13.2 +/- 2.7% (range 9-15%), and maximum change occurred 24 hr after the first dose. Rejections responsive to Solumedrol only (n = 4) showed gradual improvement of all parameters. Rejections treated with Solumedrol following failed OKT3 prophylaxis (n = 3) did not reverse and continued to show rejection associated cytologic changes and abnormal creatinines. Patients experiencing CsA toxicity (n = 12) showed mild creatinine elevations, normal or negative IL-2(P) and IL-2R(P) levels, and no IL-2(U). They showed distinctive cytologic changes consisting of swollen convoluted tubular cells with nuclear pyknosis and cytoplasmic vacuoles. Pretransplant IL-2(P) levels of patients who subsequently rejected were elevated, with 19/21 patients with preoperative IL-2 levels greater than 15 ng/ml having subsequent rejections. In contrast, pretransplant creatinine, urine cytology, and IL-2(U) levels showed no correlation to subsequent clinical course.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645701     DOI: 10.1097/00007890-198902000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  On-chip evaluation of neutrophil activation and neutrophil-endothelial cell interaction during neutrophil chemotaxis.

Authors:  Donghyuk Kim; Christy L Haynes
Journal:  Anal Chem       Date:  2013-10-28       Impact factor: 6.986

Review 3.  Renal transplant fine needle aspiration and cytokine gene expression.

Authors:  C C Nast
Journal:  Pediatr Nephrol       Date:  1995       Impact factor: 3.714

Review 4.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

5.  Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.

Authors:  R P Junghans; T A Waldmann
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

Review 6.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

7.  Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction.

Authors:  M J Dallman; C P Larsen; P J Morris
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

8.  Cytokines in clinical and experimental transplantation.

Authors:  A C Vossen; H F Savelkoul
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.